Handa Pharmaceuticals, Inc.
TPEX:6620 Stok Raporu
Handa Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6 Handa Pharmaceuticals şirketinin toplam hissedar öz sermayesi NT$2.9B ve toplam borcu NT$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$3.1B ve NT$244.7M dir. Handa Pharmaceuticals 'in FAVÖK'ü NT$525.4M faiz karşılama oranı -11.5 dur. Şirketin NT$2.5B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler Faiz karşılama oranı -11.5x Nakit NT$2.53b Eşitlik NT$2.90b Toplam yükümlülükler NT$244.70m Toplam varlıklar NT$3.15b
Son finansal sağlık güncellemeleri
Tüm güncellemeleri göster
New minor risk - Dividend sustainability Oct 25
Second quarter 2024 earnings released: EPS: NT$0.73 (vs NT$1.90 in 2Q 2023) Aug 17
Investor sentiment deteriorates as stock falls 15% Jul 29
Investor sentiment deteriorates as stock falls 17% May 30
First quarter 2024 earnings released: EPS: NT$0.83 (vs NT$1.90 in 1Q 2023) May 19
Investor sentiment improves as stock rises 16% May 13
New minor risk - Share price stability Apr 20
Investor sentiment deteriorates as stock falls 15% Apr 17
Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 03
Full year 2023 earnings released: EPS: NT$5.41 (vs NT$0.32 loss in FY 2022) Apr 03
New minor risk - Share price stability Jan 30
Third quarter 2023 earnings released: EPS: NT$1.07 (vs NT$0.18 in 3Q 2022) Dec 28
New minor risk - Share price stability Nov 17
New minor risk - Shareholder dilution Sep 10
Full year 2022 earnings released: NT$0.32 loss per share (vs NT$2.10 loss in FY 2021) Apr 22
Less than half of directors are independent Nov 16
First half 2022 earnings released: NT$0.71 loss per share (vs NT$1.01 loss in 1H 2021) Aug 17
Full year 2021 earnings released: NT$2.10 loss per share (vs NT$2.44 loss in FY 2020) Apr 30
Less than half of directors are independent Apr 27
First half 2021 earnings released: NT$1.01 loss per share (vs NT$1.26 loss in 1H 2020) Aug 18
Handa Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2021 Mar 20
New 90-day high: NT$30.70 Feb 25
Handa Pharmaceuticals'(GTSM:6620) Share Price Is Down 26% Over The Past Three Years. Feb 24
New 90-day high: NT$28.15 Jan 04
We Think Handa Pharmaceuticals (GTSM:6620) Can Afford To Drive Business Growth Dec 29
New 90-day high: NT$27.15 Nov 07
New 90-day low: NT$22.05 Sep 24
First half earnings released Aug 13
New 90-day low - NT$26.95 Aug 06
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 6620 'nin kısa vadeli varlıkları ( NT$2.8B ) kısa vadeli yükümlülüklerini ( NT$156.0M ) aşıyor.
Uzun Vadeli Yükümlülükler: 6620 şirketinin kısa vadeli varlıkları ( NT$2.8B ) uzun vadeli yükümlülüklerini ( NT$88.7M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 6620 borçsuzdur.
Borcun Azaltılması: 6620 un 5 yıl önce borcu yoktu.
Borç Kapsamı: 6620 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.
Faiz Kapsamı: 6620 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.
Sağlıklı şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}